scholarly journals Platelet-Released Growth Factors Modulate the Secretion of Cytokines in Synoviocytes under Inflammatory Joint Disease

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Mersedeh Tohidnezhad ◽  
Andreas Bayer ◽  
Biljana Rasuo ◽  
Jennifer Vanessa Phi Hock ◽  
Nisreen Kweider ◽  
...  
Keyword(s):  
Gene Expression ◽  
Platelet Rich Plasma ◽  
Joint Disease ◽  
Cytokine Gene Expression ◽  
Inflammatory Conditions ◽  
Autologous Platelet Rich Plasma ◽  
Exact Effect ◽  
Autologous Platelet ◽  
Inflammatory Effect

The etiology and pathogenesis of rheumatoid arthritis (RA) are marked by a complex interplay of various cell populations and is mediated by different signaling pathways. Traditionally, therapies have primarily focused on pain relief, reducing inflammation and the recovery of joint function. More recently, however, researchers have discussed the therapeutic efficacy of autologous platelet-rich plasma (PRP). The main objective of this work is to examine the influences of platelet-released growth factor (PRGF) on human synoviocytes under inflammatory conditions. Additionally, it is checked to which extend treatment with platelet concentrate influences the release of cytokines form synoviocytes. For this purpose, an in vitro RA model was created by stimulating the cells with the TNF-α. The release of cytokines was measured by ELISA. The cytokine gene expression was analyzed by real-time PCR. It has been observed that the stimulation concentration of 10 ng/ml TNF-α resulted in a significantly increased endogenous secretion and gene expression of IL-6 and TNF-α. The anti-inflammatory effect of PRGF could be confirmed through significant reduction of TNF-α and IL-1β. An induced inflammatory condition seems to cause PRGF to inhibit the release of proinflammatory cytokines. Further study is required to understand the exact effect mechanism of PRGF on synoviocytes.

scholarly journals Autologous Platelet-Rich Plasma Treatment Enables Pregnancy for a Woman in Premature Menopause

2018 ◽  
Vol 8 (1) ◽  
pp. 1 ◽  
Author(s):  
Konstantinos Sfakianoudis ◽  
Mara Simopoulou ◽  
Nikolaos Nitsos ◽  
Anna Rapani ◽  
Athanasios Pappas ◽  
...  
Keyword(s):  
In Vitro Fertilization ◽  
Plasma Treatment ◽  
Platelet Rich Plasma ◽  
Ovarian Tissue ◽  
Medical Knowledge ◽  
Premature Menopause ◽  
Vitro Fertilization ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

This report presents the case of a woman aged 40 who has experienced premature menopause from the age of 35. Having rejected oocyte donation, she opted for intraovarian injection of autologous platelet-rich plasma with the aim to rejuvenate the ovarian tissue and enable the employment of her own gametes through in-vitro fertilization. Six weeks following the autologous platelet-rich plasma treatment, a significant reduction in the patient’s follicle-stimulating hormone (FSH) levels were noted. A natural in-vitro fertilization cycle led to a biochemical pregnancy, resulting in a spontaneous abortion at the 5th week of pregnancy. This is the first report of a successful autologous platelet-rich plasma application leading to pregnancy in menopause. This report uniquely contributes to the medical knowledge and challenges current practice in the context of infertility. The efficiency and safety of this treatment with regard to the reproductive system merits further investigation.

In vitro effect of autologous platelet‐rich plasma on H 2 O 2 ‐induced oxidative stress in human spermatozoa

Andrology ◽  
2019 ◽  
Vol 8 (1) ◽  
pp. 191-200 ◽  
Author(s):  
R. Bader ◽  
J. N. Ibrahim ◽  
M. Moussa ◽  
A. Mourad ◽  
J. Azoury ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Platelet Rich Plasma ◽  
Human Spermatozoa ◽  
Autologous Platelet Rich Plasma ◽  
Vitro Effect ◽  
Autologous Platelet

scholarly journals Plasma Components and Platelet Activation Are Essential for the Antimicrobial Properties of Autologous Platelet-Rich Plasma: An In Vitro Study

PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e107813 ◽  
Author(s):  
Lorenzo Drago ◽  
Monica Bortolin ◽  
Christian Vassena ◽  
Carlo L. Romanò ◽  
Silvio Taschieri ◽  
...  
Keyword(s):  
Platelet Activation ◽  
Platelet Rich Plasma ◽  
Antimicrobial Properties ◽  
In Vitro Study ◽  
Vitro Study ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

scholarly journals Regenerative Effect of Intraovarian Injection of Activated Autologous Platelet Rich Plasma: Serum Anti-Mullerian Hormone Levels Measured Among Poor-Prognosis In Vitro Fertilization Patients

2020 ◽  
pp. 1-5 ◽  
Author(s):  
E. Scott Sills ◽  
E. Scott Sills ◽  
J. L. Petersen ◽  
N. S. Rickers ◽  
Samuel H. Wood ◽  
...  
Keyword(s):  
Clinical Trial ◽  
In Vitro Fertilization ◽  
Platelet Rich Plasma ◽  
Ovarian Tissue ◽  
Ovarian Response ◽  
Vitro Fertilization ◽  
Autologous Platelet Rich Plasma ◽  
Pre Treatment ◽  
Autologous Platelet

This registered, prospective clinical trial assessed serum anti-Mullerian hormone (AMH) patterns after treatment with activated platelet rich plasma (PRP). Patients with low ovarian reserve and/or at least 1 prior failed in vitro fertilization (IVF) cycle (n=182) received PRP injected into ovarian tissue under ultrasound guidance. Pretreatment AMH, BMI and platelet (PLT) concentration were recorded and serum AMH, follicle stimulating hormone, and estradiol were then measured at 2-week intervals for up to three months. Mean±SD patient age was 45.4±6.1yrs. Improved serum AMH was observed in 51 patients (28%) with median increase of 167% [95%CI 91; 280] after treatment; mean interval to maximum AMH increase was 4 weeks (range 2-10 weeks). Improved post-treatment AMH was not limited to younger patients; when stratified by age (<42 vs. ≥42yrs), significant AMH improvements were seen in both groups after treatment (p=0.03 and 0.009, respectively). Among responders, mean basal PLT count was higher (274K) vs. non-responders (250K); p<0.001. This is the first clinical trial to describe an intraovarian PRP technique for low reserve and finds the treatment safe and associated with significant increases in serum AMH for some patients, usually within four weeks. The substantially different pre-treatment PLT concentrations measured across PRP response groups warrants further investigation. Additional research can characterize ovarian response better, optimize PRP protocols, and collect outcomes data from those who subsequently undergo IVF with autologous oocytes.

Autologous platelet-rich plasma effects on Staphylococcus aureus–induced chondrocyte death in an in vitro bovine septic arthritis model

2022 ◽  
pp. 1-8
Author(s):  
Andrew J.T. Muir ◽  
Andrew J. Niehaus ◽  
Joseph W. Lozier ◽  
Sara L. Cole ◽  
Zarah A. Belacic ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Septic Arthritis ◽  
Metabolic Activity ◽  
Culture Medium ◽  
Platelet Rich Plasma ◽  
Cartilage Explants ◽  
Chondrocyte Death ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

Abstract OBJECTIVE To investigate the chondroprotective effects of autologous platelet-rich plasma (PRP), ampicillin-sulbactam (AmpS), or PRP combined with AmpS (PRP+AmpS) in an in vitro chondrocyte explant model of bovine Staphylococcus aureus–induced septic arthritis. SAMPLE Autologous PRP and cartilage explants obtained from 6 healthy, adult, nonlactating Jersey-crossbred cows. ProcedureS Autologous PRP was prepared prior to euthanasia using an optimized double centrifugation protocol. Cartilage explants collected from grossly normal stifle joints were incubated in synovial fluid (SF) alone, S aureus–inoculated SF (SA), or SA supplemented with PRP (25% culture medium volume), AmpS (2 mg/mL), or both PRP (25% culture medium volume) and AmpS (2 mg/mL; PRP+AmpS) for 24 hours. The metabolic activity, percentage of dead cells, and glycosaminoglycan content of cartilage explants were measured with a resazurin-based assay, live-dead cell staining, and dimethylmethylene blue assay, respectively. Treatment effects were assessed relative to the findings for cartilage explants incubated in SF alone. RESULTS Application of PRP, AmpS, and PRP+AmpS treatments significantly reduced S aureus–induced chondrocyte death (ie, increased metabolic activity and cell viability staining) in cartilage explants, compared with untreated controls. There were no significant differences in chondrocyte death among explants treated with PRP, AmpS, or PRP+AmpS. CLINICAL RELEVANCE In this in vitro explant model of S aureus–induced septic arthritis, PRP, AmpS, and PRP+AmpS treatments mitigated chondrocyte death. Additional work to confirm the efficacy of PRP with bacteria commonly associated with clinical septic arthritis in cattle as well as in vivo evaluation is warranted.

Live Birth After an Autologous Platelet-Rich Plasma Ovarian In Vitro Activation and Bone Marrow Stem Cells Transplantation in a Premature Ovarian Failure Case Report

2021 ◽  
Author(s):  
Aleksandar Ljubić ◽  
Tatjana Božanović ◽  
Andrea Pirkovic-Cabarkapa ◽  
Andjela Perovic ◽  
Dušica Ljubić ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Ovarian Function ◽  
Platelet Rich Plasma ◽  
Ovarian Tissue ◽  
Follicular Growth ◽  
Hormonal Function ◽  
Autologous Platelet Rich Plasma ◽  
Natural Conception ◽  
Autologous Platelet

Abstract Background: Patients with premature ovarian failure (POF) exhibit a diminished ovarian reserve and hormonal dysfunction. Case presentation: We aimed to restore normal hormonal function and folliculogenesis in a 31-year-old patient with POF, who had been amenorrheic for two years. We designed and performed three different ovarian regeneration procedures for three consecutive years, from 2015 to 2017: 1) intraovarian injection of activated autologous platelet-rich plasma (PRP); 2) activated autologous PRP and bone marrow-derived stem cell injection into the ovaries (SEGO); 3) ovarian cortical tissue resection and fragmentation; and in vitro ovarian tissue activation with autologous PRP and bone marrow stem cell retransplantation into the ovaries (the SEGOVA). The patient exhibited no improvement following the PRP treatment. The patient regained regular menstrual cycles after the SEGO procedure, although no follicular growth was observed yet. One month after the SEGOVA procedure, follicular growth was detected, and the patient underwent several stimulation protocols without obtaining oocytes. Eight months after the SEGOVA, the patient underwent in vitro fertilization (IVF) in a spontaneous cycle, when an oocyte of good quality was retrieved. Following intracytoplasmic sperm injection (ICSI), the oocyte failed to be fertilized. Eleven months after the SEGOVA, the patient reported a spontaneous pregnancy via natural conception. Pregnancy resulted in birth at term by uncomplicated vaginal delivery. After three different ovarian rejuvenation procedures, normal hormonal function and follicular growth were restored in the patient with POF, and the patient had a successful natural pregnancy following the last SEGOVA procedure. Although no ovarian function was detected after the first two procedures, they may have contributed to the outcomes from the SEGOVA procedure, a treatment that showed promising results in recovering ovarian function in patients with POF. Conclusions: It cannot be ruled out that ovarian rejuvenation with bone marrow‑derived stem cells and autologous growth factors, together with ovarian tissue fragmentation, took time to exhibit its effects and contributed to the final result – a successful natural conception and pregnancy.

scholarly journals Optimization of Lyophilized Hyperacute Serum (HAS) as a Regenerative Therapeutic in Osteoarthritis

2021 ◽  
Vol 22 (14) ◽  
pp. 7496
Author(s):  
Isabel Olmos Calvo ◽  
Olga Kuten-Pella ◽  
Karina Kramer ◽  
Ágnes Madár ◽  
Szilvia Takács ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Analysis ◽  
Platelet Rich Plasma ◽  
Cell Types ◽  
Inflammatory Conditions ◽  
Osteoarthritic Chondrocytes ◽  
Prp Gene ◽  
Human Explants ◽  
Cytokine Quantification

Hyperacute serum (HAS) is a blood derivative product that promotes the proliferation of various cell types and controls inflammation in vitro. The aim of this study is to investigate the regenerative potential of different formulations of HAS, including lyophilized and hyaluronic acid combined versions, to obtain a stable and standardized therapeutic in osteoarthritis (OA), which may be able to overcome the variability limitations of platelet-rich plasma (PRP). Primary human osteoarthritic chondrocytes were used for testing cellular viability and gene expression of OA-related genes. Moreover, a co-culture of human explants of cartilage, bone and synovium under inflammatory conditions was used for investigating the inflammatory control capacities of the different therapeutics. In this study, one formulation of lyophilized HAS achieved the high cell viability rates of liquid HAS and PRP. Gene expression analysis showed that HAS induced higher Col1a1 expression than PRP. Cytokine quantification from supernatant fluids revealed that HAS treatment of inflamed co-cultures significantly reduced levels of IL-5, IL-15, IL-2, TNFα, IL-7 and IL-12. To conclude, lyophilized HAS is a stable and standardized therapeutic with high potential in joint regeneration.

Sign in / Sign up

Export Citation Format

Share Document